Balyasny Asset Management
VTAE

Balyasny Asset Management’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Balyasny Asset Management’s Portfolio VTAE Stock Details VTAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-301,086
Closed -$3.25M – 1451
2016
Q2 		$3.25M Buy
301,086
+21,930
+8% +$188K 0.02% 598
2016
Q1 		$1.85M Buy
279,156
+163,356
+141% +$1.49M 0.01% 707
2015
Q4 		$2.1M Buy
+115,800
New +$1.59M 0.01% 643

Other funds holding VTAE

AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management's VTAE Position: Q3 2016 in Review

Balyasny Asset Management sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q3 2016, closing a stake of 301,086 shares — an estimated $3.25M sold.

Balyasny Asset Management first reported a position in VTAE in Q4 2015 and held it in 3 quarters. The position peaked at $3.25M in Q2 2016. 98 funds tracked by Wall St. Rank hold VTAE as of Q3 2016.

  • Balyasny Asset Management reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q3 2016 after selling out during the quarter.
  • Balyasny Asset Management sold 301,086 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q3 2016, an estimated $3.25M.
  • Balyasny Asset Management first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2015 and held it in 3 quarters.
  • Balyasny Asset Management's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $3.25M in Q2 2016.
  • 98 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q3 2016.

Based on Balyasny Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.